Table 3. Univariate analysis of previously described prognostic factors for PFS and OS on first-line anti-VEGFR-TKI.
| Median PFS (months) | HR (95% CI) P (UV) | Median OS (months) | HR (95% CI) P (UV) | |
|---|---|---|---|---|
| Neutrophil count >4.500 mm−3 (n=54) | 8 | 1.81 (1.18–2.79) | 21 | 1.57 (1.02–2.42) |
| Neutrophil count ⩽4.500 mm−3 (n=73) | 17 | 0.007 | 34 | 0.04 |
| Platelet count >400.000 mm−3 (n=17) | 7 | 2.35 (1.12–4.95) | 17 | 1.63 (0.82–3.26) |
| Platelet count ⩽400.000 mm−3 (n=110) | 14 | 0.03 | 27 | 0.17 |
| Karnofsky PS ⩽70 (n=15) | 4 | 9.08 (3.59–22.93) | 9 | 16.97 (6.00–47.96) |
| Karnofsky PS >70 (n=110) | 14 | <0.0001 | 27 | <0.0001 |
| LDH >1.5 ULN (n=9) | 19 | 1.21 (0.52–2.82) | 27 | 1.17 (0.54–2.56) |
| LDH ⩽≤1.5 ULN (n=111) | 12 | 0.66 | 26 | 0.69 |
| Hb<11.5 (women) or 13 g dl−1 (men) (n=52) | 10 | 1.62 (1.05–2.48) | 22 | 1.52 (0.98–2.35) |
| Hb normal (n=74) | 16 | 0.03 | 30 | 0.06 |
| Corrected calcium >10 mg dl−1 (n=6) | 24.5 | 0.67 (0.29–1.54) | 36.5 | 0.76 (0.31–1.85) |
| Corrected calcium ⩽10 mg dl−1 (n=113) | 12 | 0.34 | 25 | 0.54 |
| Time from diagnosis to systemic treatment <1 year (n=82) | 12 | 1.58 (1.04–2.40) | 25 | 1.55 (1.01–2.39) |
| Time from diagnosis to systemic treatment >1 year (n=43) | 13 | 0.03 | 26 | 0.04 |
| Liver metastases at start of sunitinib (n=20) | 8 | 2.18 (1.14–4.17) | 15.5 | 3.04 (1.49–6.20) |
| No liver metastases at start of sunitinib (n=109) | 14 | 0.02 | 28 | 0.002 |
| Bone metastases at start of sunitinib (n=37) | 9 | 1.53 (0.96–2.43) | 22 | 1.74 (1.06–2.84) |
| No bone metastases at start of sunitinib (n=92) | 13 | 0.07 | 30 | 0.03 |
| Sarcomatoid dedifferentiation ⩾25% (n=10) | 6 | 4.51 (1.57–13.01) | 14 | 9.10 (2.98–28.01) |
| Sarcomatoid dedifferentiation <25% (n=115) | 14 | 0.005 | 28 | 0.0001 |
| No previous immunotherapy (n=94) | 11 | 1.06 (0.67–1.67) | 24 | 1.21 (0.77–1.90) |
| Previous immunotherapy (n=33) | 15 | 0.81 | 34 | 0.41 |
| IMDC poor risk (n=16) | 7 | 0.0003 | 17 | 0.0003 |
| IMDC intermediate risk (n=73) | 14 | 27 | ||
| IMDC good risk (n=33) | 25 | Not reached | ||
| Ccrcc1 (n=38) | 12 | 0.0001 | 22 | <0.0001 |
| Ccrcc2 (n=47) | 19 | 50 | ||
| Ccrcc3 (n=14) | 19.5 | 50 | ||
| Ccrcc4 (n=17) | 5 | 11 |
Abbreviations: CI=confidence interval; Hb=haemoglobin; HR=hazard ratio; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; LDH=lactate dehydrogenase; OS=overall survival; PFS=progression-free survival; UV=univariate.